Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Kristen Kluska
CANT
Kristen Kluska
Cantor Fitzgerald
Wall Street Analyst
★☆☆☆☆
#2474
on 13Foresight · ranked by our own returns
41%
Success Rate
-9.2%
Average Return
17 of 41 calls profitable · -19.2% vs benchmark
📈 Across the calls we could measure, roughly 41% of Kristen Kluska's ratings turned a profit when each position was held for 1 year — averaging -9.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

124 Buy 19 Hold 0 Sell
Kristen's Stock Coverage 46 ratings · 2026-06-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
QURE
uniQure
 Jun 17, 2026 BUY Strong Buy
+16.1% avg upside
29 analysts
 — ·
CDXS
Codexis
 Jun 16, 2026 BUY Strong Buy
+291.5% avg upside
13 analysts
$11.00
327.93% Upside
 ·
CLDX
Celldex
 Jun 14, 2026 BUY Strong Buy
+20.6% avg upside
28 analysts
$67.00
106.59% Upside
 +0.8%
ZVRA
Zevra Therapeutics
 Jun 08, 2026 BUY Strong Buy
+85.3% avg upside
15 analysts
$34.00
163.50% Upside
 +4.3%
RARE
Ultragenyx Pharmaceutical
 May 20, 2026 BUY Strong Buy
+142.1% avg upside
36 analysts
$96.00
249.82% Upside
 ·
MNPR
Monopar Therapeutics Inc
 May 14, 2026 BUY Strong Buy
+45.9% avg upside
18 analysts
$109.00
61.53% Upside
 -2.8%
CAPR
Capricor Therapeutics
 May 12, 2026 BUY Strong Buy
+68.2% avg upside
12 analysts
$62.00
118.43% Upside
 -8.7%
IRON
Disc Medicine
 May 12, 2026 BUY Strong Buy
+20.2% avg upside
21 analysts
$125.00
76.51% Upside
 +2.3%
MREO
Mereo Biopharma Group Plc
 May 12, 2026 BUY Strong Buy
+1152.4% avg upside
11 analysts
$3.00
869.56% Upside
 -4.0%
SLDB
Solid Biosciences
 May 12, 2026 BUY Strong Buy
+90.3% avg upside
23 analysts
$16.00
92.18% Upside
 -10.4%
ESPR
Esperion
 May 01, 2026 HOLD Buy
+701.2% avg upside
22 analysts
$3.16
0.25% Upside
 +1.3%
DBVT
DBV Technologies SA - American
 Apr 30, 2026 BUY Strong Buy
+55.4% avg upside
15 analysts
$48.00
209.01% Upside
 -22.5%
RNAC
Cartesian Therapeutics
 Apr 30, 2026 BUY Strong Buy
+228.2% avg upside
19 analysts
$16.00
66.09% Upside
 +43.2%
PTCT
PTC Therapeutics
 Apr 28, 2026 BUY Buy
-1.5% avg upside
29 analysts
$124.00
57.09% Upside
 +11.8%
TSE:EPRX
Eupraxia Pharmaceuticals
 Mar 31, 2026 BUY Strong Buy
+147.7% avg upside
8 analysts
$26.87
196.60% Upside
 ·
LXEO
Lexeo Therapeutics, Inc.
 Mar 30, 2026 BUY Strong Buy
+313.8% avg upside
11 analysts
$19.00
285.45% Upside
 -3.4%
ADMA
ADMA Biologics
 Mar 25, 2026 HOLD Strong Buy
+57.2% avg upside
15 analysts
$30.00
260.93% Upside
 -12.6%
TSHA
Taysha Gene Therapies
 Mar 24, 2026 BUY Strong Buy
+102.5% avg upside
21 analysts
$19.00
195.89% Upside
 +49.9%
FULC
Fulcrum Therapeutics
 Mar 19, 2026 BUY Hold
+138.4% avg upside
13 analysts
$24.00
548.74% Upside
 -5.0%
SRPT
Sarepta Therapeutics
 Mar 16, 2026 HOLD Buy
+244.5% avg upside
49 analysts
$21.00
19.80% Upside
 -5.5%
SKYE
Skye Bioscience
 Mar 10, 2026 HOLD Strong Buy
+1354.2% avg upside
9 analysts
$2.00
182.79% Upside
 +1.4%
RIGL
Rigel
 Mar 03, 2026 HOLD Strong Buy
-27.5% avg upside
17 analysts
$38.00
15.53% Upside
 -0.9%
AQST
Aquestive Therapeutics
 Mar 02, 2026 BUY Strong Buy
+88.9% avg upside
10 analysts
$11.00
133.49% Upside
 +2.3%
SUPN
Supernus Pharmaceuticals
 Feb 24, 2026 BUY Strong Buy
+21.7% avg upside
7 analysts
$63.00
42.04% Upside
 -7.3%
ABEO
Abeona Therapeutics
 Feb 23, 2026 BUY Strong Buy
+195.8% avg upside
17 analysts
$28.00
385.28% Upside
 +5.2%
PHAT
Phathom Pharmaceuticals
 Jan 13, 2026 BUY Strong Buy
+163.8% avg upside
14 analysts
$29.00
166.58% Upside
 -30.4%
XFOR
X4 Pharmaceuticals
 Nov 21, 2025 BUY Strong Buy
+491.4% avg upside
15 analysts
$14.00
231.84% Upside
 +8.8%
HUMA
Humacyte
 Jul 01, 2024 BUY Strong Buy
+665.4% avg upside
11 analysts
$7.00
657.29% Upside
 -57.5%
IRD
Opus Genetics
 May 13, 2024 BUY Strong Buy
+154.5% avg upside
23 analysts
 — -20.0%
LCTX
Lineage Therap
 Feb 04, 2024 BUY Strong Buy
+342.7% avg upside
16 analysts
$6.00
395.90% Upside
 -36.5%
OTLK
Outlook Therapeutics
 Aug 30, 2023 HOLD Buy
+484.7% avg upside
11 analysts
$20.00
1165.87% Upside
 +36.6%
DRTS
Alpha Tau Medical Ltd
 Aug 28, 2023 BUY Strong Buy
+41.1% avg upside
5 analysts
$23.00
135.16% Upside
 -30.1%
ATNM
Actinium Pharmaceuticals
 Jun 28, 2023 BUY Strong Buy
+633.5% avg upside
11 analysts
$27.00
2521.36% Upside
 +0.5%
DMRA
Damora Therapeutics
 Jun 26, 2023 BUY Strong Buy
+28.3% avg upside
19 analysts
$17.00
19.97% Downside
 ·
CMMB
Chemomab Therapeutics
 Jun 09, 2023 HOLD Strong Buy
+1689.5% avg upside
6 analysts
 — -41.7%
HEPA
Hepion Pharmaceuticals
 May 15, 2023 BUY Strong Buy
+82042.8% avg upside
9 analysts
$28.00
46566.65% Upside
 ·
EVLO
Evelo Biosciences
 Mar 16, 2023 HOLD Buy
+4499999900.0% avg upside
5 analysts
$20.00
1999999899.94% Upside
 ·
HTGMQ
HTG Molecular Diagnostics
 Mar 10, 2023 HOLD Buy
+7333233.3% avg upside
6 analysts
 — ·
PHGE
BiomX
 Mar 10, 2023 HOLD Buy
+4708.6% avg upside
4 analysts
 — +28.2%
IBIO
Ibio
 Dec 21, 2022 HOLD Strong Buy
+244.7% avg upside
11 analysts
$10.00
491.76% Upside
 -84.8%
GLMD
Galmed Pharmaceuticals
 Aug 04, 2022 HOLD Buy
+4113.3% avg upside
13 analysts
$10.50
1710.28% Upside
 -84.4%
ERNA
Eterna Therapeutics
 Dec 29, 2021 BUY Strong Buy
+1061.3% avg upside
4 analysts
$180.00
2803.14% Upside
 -96.3%
OCGN
Ocugen
 Sep 28, 2021 HOLD Strong Buy
+645.9% avg upside
17 analysts
$4.00
222.51% Upside
 -71.6%
MBIO
Mustang Bio
 May 12, 2021 BUY Strong Buy
+938.4% avg upside
5 analysts
$10.00
1438.44% Upside
 -77.2%
SCPX
Scorpius Holdings
 Mar 02, 2021 BUY Strong Buy
+1664672.8% avg upside
11 analysts
$22.00
1999900.05% Upside
 ·
EVGN
Evogene
 Nov 30, 2020 BUY Strong Buy
+1967.8% avg upside
6 analysts
$9.00
1613.93% Upside
 -42.6%
🔒 41 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Kristen Kluska — Frequently Asked Questions
How accurate are Kristen Kluska's stock ratings?
Based on the calls 13Foresight could measure, about 41% of Kristen's ratings were profitable over a one-year hold, with an average return of -9.2% per rating, or -19.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Kristen ranked on 13Foresight?
Kristen Kluska is currently ranked #2474 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Kristen cover?
Kristen most recently has ratings on QURE, CDXS, CLDX, ZVRA, RARE, MNPR, CAPR, IRON, MREO, SLDB, ESPR, DBVT and 34 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.